Peg, Look at the two year chart on this stock and you'll see the big spikes and subsequent sell offs in PSDV. Illuvien should get approval as the drug itself has been approved by the the FDA, not for this indication however. PSDV has two FDA approved delivery systems. This system represents their most advanced. PFE just recently jumped on board with a modified agreement with PSDV to develop another opthalmic drug for glaucoma.This demonstrates some confidence. PFE is also a 10% owner of PSDV. Approval of Illuvien will triple the market cap of this nano technology company. As the market cap for this company is under 100 MIL, it's thinly traded and subject to volatility, thus an opportunity in accumulating shares on the dips. Good luck.
The "word on the street" is around 80 per cent. My sources are usually highly accurate. The question, however, is how to play the stock. It doesn't seem to be getting much attention on the run up to a potential approval date and it is always risky to hold and allow FDA to dictate your future. I am avoiding for those reasons, but if you are a true believer, go for it.